Keyphrases
In Vivo Effects
100%
Glucose Disposal
100%
Protease Inhibitors
100%
HIV Protease Inhibitors
100%
Atazanavir
60%
Drug Levels
40%
Ritonavir
40%
Lopinavir
40%
Amprenavir
40%
2-Deoxyglucose Uptake
40%
Glucose Homeostasis
20%
Insulin Resistance
20%
HIV Patients
20%
Clinical Application
20%
Dose Effect
20%
Skeletal muscle
20%
Rat Adipocytes
20%
Steady State
20%
Rodent Models
20%
Glucose Uptake
20%
Preclinical Testing
20%
Male Rats
20%
Rank Order
20%
Peripheral Insulin Resistance
20%
Impaired Glucose Tolerance
20%
Future Risk
20%
In Vivo Efficacy
20%
Hyperinsulinemic-euglycemic Clamp
20%
Continuous Intravenous Infusion
20%
Medicine and Dentistry
Proteinase Inhibitor
100%
Human Immunodeficiency Virus Proteinase Inhibitor
100%
Atazanavir
60%
In Vitro
40%
Insulin Resistance
40%
Deoxyglucose
40%
Amprenavir
40%
Lopinavir/Ritonavir
40%
Human Immunodeficiency Virus
20%
Glucose Uptake
20%
Intravenous Drug Administration
20%
Steady State
20%
Glucose Homeostasis
20%
Impaired Glucose Tolerance
20%
Ritonavir
20%
Skeletal Muscle
20%
Adipocyte
20%
Neuroscience
In Vivo
100%
Proteinase
100%
Human Immunodeficiency Virus Proteinase
100%
Atazanavir
60%
In Vitro
40%
2-Deoxy-D-Glucose
40%
Amprenavir
40%
Lopinavir/Ritonavir
40%
Human Immunodeficiency Virus
20%
Glucose Transport
20%
Adipocyte
20%
Skeletal Muscle
20%
Ritonavir
20%
Pharmacology, Toxicology and Pharmaceutical Science
Proteinase Inhibitor
100%
Human Immunodeficiency Virus Proteinase Inhibitor
100%
Atazanavir
60%
Insulin Resistance
40%
Deoxyglucose
40%
Lopinavir Plus Ritonavir
40%
Amprenavir
40%
HIV
20%
Ritonavir
20%
Impaired Glucose Tolerance
20%